TAF7

Across TCGA pan-cancer cohorts, TAF7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAF7 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TAF7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TAF7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where TAF7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.633	0.850	.014	14	view →
LSCC	OS	Tertile	III,IV	0.536	0.918	.010	12	view →
LUAD	OS	Quartile	III,IV	0.719	0.236	.012	5	view →
UCEC	DFS	Median	All	0.928	0.793	.041	4	view →
HNSC	DFS	Quartile	All	0.500	0.764	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TAF7–CCRCC (DFS)

Open the CCRCC breakdown →